← All stories
Markets
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones Acquisition of Theravance Biopharma, In…
Covered by 1 outlet
All coverage · 1 article